Kuros Biosciences AG
SIX:KURN

Watchlist Manager
Kuros Biosciences AG Logo
Kuros Biosciences AG
SIX:KURN
Watchlist
Price: 28.04 CHF 3.77% Market Closed
Market Cap: 1.1B CHF

Kuros Biosciences AG
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Kuros Biosciences AG
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Kuros Biosciences AG
SIX:KURN
Net Income (Common)
-CHf7.1m
CAGR 3-Years
14%
CAGR 5-Years
10%
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Net Income (Common)
-$166.9m
CAGR 3-Years
0%
CAGR 5-Years
6%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Net Income (Common)
-$488.3m
CAGR 3-Years
10%
CAGR 5-Years
-18%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Net Income (Common)
CHf72.7m
CAGR 3-Years
340%
CAGR 5-Years
90%
CAGR 10-Years
N/A
Idorsia Ltd
SIX:IDIA
Net Income (Common)
-CHf117.9m
CAGR 3-Years
49%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Relief Therapeutics Holding SA
SIX:RLF
Net Income (Common)
-CHf17m
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Kuros Biosciences AG
Glance View

Market Cap
1.1B CHF
Industry
Biotechnology

Kuros Biosciences Ltd. engages in the discovery, development and prospective commercialization of a new class of biopharmaceutical products that are intended for use in the treatment and prevention of chronic diseases. The company is headquartered in Schlieren, Zuerich and currently employs 58 full-time employees. The company went IPO on 2002-10-29. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The firm has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The firm has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.

KURN Intrinsic Value
37.95 CHF
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Kuros Biosciences AG's Net Income (Common)?
Net Income (Common)
-7.1m CHF

Based on the financial report for Jun 30, 2025, Kuros Biosciences AG's Net Income (Common) amounts to -7.1m CHF.

What is Kuros Biosciences AG's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
10%

Over the last year, the Net Income (Common) growth was 35%. The average annual Net Income (Common) growth rates for Kuros Biosciences AG have been 14% over the past three years , 10% over the past five years .

Back to Top